FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3005532033> ?p ?o ?g. }

• W3005532033 endingPage "370" @default.
• W3005532033 startingPage "363" @default.
• W3005532033 abstract "BACKGROUND: Liver-directed hepatic arterial therapies are associated with improved survival and effective symptom control for patients with unresectable neuroendocrine liver metastases (NELM). Whether transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) with yttrium-90 (y-90) are associated with improved short- or long-term outcomes is unknown. STUDY DESIGN: A retrospective review was performed of all patients with NELM undergoing transarterial therapies, from 2000 to 2018, at 2 academic medical centers. Postoperative morbidity, radiographic response according to response evaluation criteria in solid tumors (RECIST) criteria, and long-term outcomes were compared between patients who underwent TACE vs TARE. RESULTS: Among 248 patients with NELM, 197 (79%) received TACE and 51 (21%) received TARE. While patients who underwent TACE were more likely to have carcinoid syndrome, larger tumors, and higher chromogranin A levels, there was no difference in tumor differentiation, primary site, bilobar disease, or synchronous presentation. Nearly all TARE treatments (92%) were performed as outpatient procedures, while 99% of TACE patients spent at least 1 night in the hospital. There were no differences in overall morbidity (TARE 13.7% vs TACE 22.6%, p = 0.17), grade III/IV complication (5.9% vs 9.2%, p = 0.58), or 90-day mortality. The disease control rate (DCR) on first post-treatment imaging (RECIST partial/complete response or stable disease) was greater for TACE compared with TARE (96% vs 83%, p < 0.01). However, there was no difference in median overall survival (OS, 35.9 months vs 50.1 months, p = 0.3) or progression-free survival (PFS, 15.9 months vs 19.9 months, p = 0.37). CONCLUSIONS: In this retrospective multi-institutional analysis, both TACE and TARE with Y-90 were safe and effective liver-directed therapies for unresectable NELM. Although TARE was associated with a shorter length of hospital stay, TACE demonstrated improved short-term DCR, and both resulted in comparable long term outcomes." @default.
• W3005532033 created "2020-02-14" @default.
• W3005532033 creator A5002070760 @default.
• W3005532033 creator A5011696445 @default.
• W3005532033 creator A5030505421 @default.
• W3005532033 creator A5035552610 @default.
• W3005532033 creator A5036473043 @default.
• W3005532033 creator A5057140415 @default.
• W3005532033 creator A5069026924 @default.
• W3005532033 creator A5071286571 @default.
• W3005532033 creator A5071405425 @default.
• W3005532033 creator A5086651983 @default.
• W3005532033 date "2020-04-01" @default.
• W3005532033 modified "2023-10-17" @default.
• W3005532033 title "Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis" @default.
• W3005532033 cites W1505768107 @default.
• W3005532033 cites W1988370994 @default.
• W3005532033 cites W2006821285 @default.
• W3005532033 cites W2011124928 @default.
• W3005532033 cites W2013603665 @default.
• W3005532033 cites W2015149820 @default.
• W3005532033 cites W2018338654 @default.
• W3005532033 cites W2023215996 @default.
• W3005532033 cites W2060500454 @default.
• W3005532033 cites W2065170253 @default.
• W3005532033 cites W2069999129 @default.
• W3005532033 cites W2082891425 @default.
• W3005532033 cites W2096998881 @default.
• W3005532033 cites W2117668987 @default.
• W3005532033 cites W2149214723 @default.
• W3005532033 cites W2159794412 @default.
• W3005532033 cites W2176186007 @default.
• W3005532033 cites W2522256404 @default.
• W3005532033 cites W2530769955 @default.
• W3005532033 cites W2608160487 @default.
• W3005532033 cites W2725873592 @default.
• W3005532033 cites W2770632840 @default.
• W3005532033 cites W2802187292 @default.
• W3005532033 cites W2898401583 @default.
• W3005532033 cites W2906498735 @default.
• W3005532033 cites W2907788633 @default.
• W3005532033 cites W2966218013 @default.
• W3005532033 doi "https://doi.org/10.1016/j.jamcollsurg.2019.12.026" @default.
• W3005532033 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32032719" @default.
• W3005532033 hasPublicationYear "2020" @default.
• W3005532033 type Work @default.
• W3005532033 sameAs 3005532033 @default.
• W3005532033 citedByCount "44" @default.
• W3005532033 countsByYear W30055320332020 @default.
• W3005532033 countsByYear W30055320332021 @default.
• W3005532033 countsByYear W30055320332022 @default.
• W3005532033 countsByYear W30055320332023 @default.
• W3005532033 crossrefType "journal-article" @default.
• W3005532033 hasAuthorship W3005532033A5002070760 @default.
• W3005532033 hasAuthorship W3005532033A5011696445 @default.
• W3005532033 hasAuthorship W3005532033A5030505421 @default.
• W3005532033 hasAuthorship W3005532033A5035552610 @default.
• W3005532033 hasAuthorship W3005532033A5036473043 @default.
• W3005532033 hasAuthorship W3005532033A5057140415 @default.
• W3005532033 hasAuthorship W3005532033A5069026924 @default.
• W3005532033 hasAuthorship W3005532033A5071286571 @default.
• W3005532033 hasAuthorship W3005532033A5071405425 @default.
• W3005532033 hasAuthorship W3005532033A5086651983 @default.
• W3005532033 hasConcept C126322002 @default.
• W3005532033 hasConcept C126838900 @default.
• W3005532033 hasConcept C141071460 @default.
• W3005532033 hasConcept C167135981 @default.
• W3005532033 hasConcept C2778822529 @default.
• W3005532033 hasConcept C2779066768 @default.
• W3005532033 hasConcept C2779134260 @default.
• W3005532033 hasConcept C2779984678 @default.
• W3005532033 hasConcept C71924100 @default.
• W3005532033 hasConcept C81182388 @default.
• W3005532033 hasConcept C90924648 @default.
• W3005532033 hasConceptScore W3005532033C126322002 @default.
• W3005532033 hasConceptScore W3005532033C126838900 @default.
• W3005532033 hasConceptScore W3005532033C141071460 @default.
• W3005532033 hasConceptScore W3005532033C167135981 @default.
• W3005532033 hasConceptScore W3005532033C2778822529 @default.
• W3005532033 hasConceptScore W3005532033C2779066768 @default.
• W3005532033 hasConceptScore W3005532033C2779134260 @default.
• W3005532033 hasConceptScore W3005532033C2779984678 @default.
• W3005532033 hasConceptScore W3005532033C71924100 @default.
• W3005532033 hasConceptScore W3005532033C81182388 @default.
• W3005532033 hasConceptScore W3005532033C90924648 @default.
• W3005532033 hasIssue "4" @default.
• W3005532033 hasLocation W30055320331 @default.
• W3005532033 hasOpenAccess W3005532033 @default.
• W3005532033 hasPrimaryLocation W30055320331 @default.
• W3005532033 hasRelatedWork W2121180524 @default.
• W3005532033 hasRelatedWork W2591156603 @default.
• W3005532033 hasRelatedWork W2895829217 @default.
• W3005532033 hasRelatedWork W2899528185 @default.
• W3005532033 hasRelatedWork W2976273518 @default.
• W3005532033 hasRelatedWork W3008278826 @default.
• W3005532033 hasRelatedWork W3012367642 @default.
• W3005532033 hasRelatedWork W3112168726 @default.
• W3005532033 hasRelatedWork W4283078509 @default.

• next